Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity
- PMID: 7729864
- PMCID: PMC173200
- DOI: 10.1128/iai.63.5.1617-1623.1995
Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity
Abstract
The heat-labile enterotoxin (LT) of Escherichia coli is immunologically and physiochemically related to cholera enterotoxin. A number of studies have been performed to determine the relationship of the ADP-ribosylating enzymatic activity of these enterotoxins to toxicity and adjuvanticity. These studies have generally examined the effect of abolishing the ADP-ribosyltransferase activity of A1 by a variety of chemical or genetic manipulations. In every case, loss of enzymatic activity was associated with loss of biological activity and also with the ability of the molecules to function as oral adjuvants. Consequently, we explored an alternate approach to detoxification of LT without altering its adjuvanticity. Specifically, we generated a novel mutant form of LT by genetic modification of the proteolytically sensitive residues that join the A1 and A2 components of the A subunit. This mutant contains a single amino acid substitution within the disulfide subtended region joining A1 and A2. This mutant toxin, designated LT(R192G), is not sensitive to proteolytic activation, has negligible activity on mouse Y-1 adrenal tumor cells, and is devoid of ADP-ribosyltransferase activity. Nonetheless, LT(R192G) retains the ability to function as a mucosal adjuvant, increasing the serum immunoglobulin G (IgG) and mucosal IgA responses to coadministered antigen (OVA) beyond that achieved with administration of that antigen alone. Further, LT(R192G) prevented the induction of tolerance to coadministered antigen and did not induce tolerance against itself, as demonstrated by the presence of significant serum anti-LT IgG and mucosal anti-LT IgA antibodies in immunized mice.
Similar articles
-
Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity.J Exp Med. 1998 Apr 6;187(7):1123-32. doi: 10.1084/jem.187.7.1123. J Exp Med. 1998. PMID: 9529328 Free PMC article.
-
The mucosal adjuvanticity of two nontoxic mutants of Escherichia coli heat-labile enterotoxin varies with immunization routes.Exp Mol Med. 2000 Jun 30;32(2):72-8. doi: 10.1038/emm.2000.13. Exp Mol Med. 2000. PMID: 10926118
-
Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants.Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1644-8. doi: 10.1073/pnas.92.5.1644. Proc Natl Acad Sci U S A. 1995. PMID: 7878032 Free PMC article.
-
The role of ADP-ribosylation and G(M1)-binding activity in the mucosal immunogenicity and adjuvanticity of the Escherichia coli heat-labile enterotoxin and Vibrio cholerae cholera toxin.Immunol Cell Biol. 1998 Jun;76(3):270-9. doi: 10.1046/j.1440-1711.1998.00745.x. Immunol Cell Biol. 1998. PMID: 9682971 Review.
-
A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine.Jpn J Infect Dis. 2000 Jun;53(3):98-106. Jpn J Infect Dis. 2000. PMID: 10957706 Review.
Cited by
-
Pathogen-induced secretory diarrhea and its prevention.Eur J Clin Microbiol Infect Dis. 2016 Nov;35(11):1721-1739. doi: 10.1007/s10096-016-2726-5. Epub 2016 Jul 29. Eur J Clin Microbiol Infect Dis. 2016. PMID: 27473379 Review.
-
Antibody-independent protection against rotavirus infection of mice stimulated by intranasal immunization with chimeric VP4 or VP6 protein.J Virol. 1999 Sep;73(9):7574-81. doi: 10.1128/JVI.73.9.7574-7581.1999. J Virol. 1999. PMID: 10438847 Free PMC article.
-
Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants.Infect Immun. 1999 Sep;67(9):4400-6. doi: 10.1128/IAI.67.9.4400-4406.1999. Infect Immun. 1999. PMID: 10456880 Free PMC article.
-
Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses.J Virol. 2001 Oct;75(20):9713-22. doi: 10.1128/JVI.75.20.9713-9722.2001. J Virol. 2001. PMID: 11559804 Free PMC article.
-
Recent advances in vaccine adjuvants.Pharm Res. 2002 Jun;19(6):715-28. doi: 10.1023/a:1016104910582. Pharm Res. 2002. PMID: 12134940 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous